Metabolically Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)

Abstract Background: Obesity is a risk factor for endometrial cancer but whether metabolic dysfunction is associated with endometrial cancer independent of body size is not known. Methods: The association of metabolically defined body size phenotypes with endometrial cancer risk was investigated in a nested case–control study (817 cases/ 817 controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of C-peptide were used to define metabolically healthy (MH; <1st tertile) and metabolically unhealthy (MU; ≥1st tertile) status among the control participants. These metabolic health definitions were combined with normal weight (NW); body mass index (BMI)<25 kg/m2 or waist circumference (WC)<80 cm or waist-to-hip ratio (WHR)<0.8) and overweight (OW; BMI≥25 kg/m2 or WC≥80 cm or WHR≥0.8) status, generating four phenotype groups for each anthropometric measure: (i) MH/NW, (ii) MH/OW, (iii) MU/NW, and (iv) MU/OW. Results: In a multivariable-adjusted conditional logistic regression model, compared with MH/NW individuals, endometrial cancer risk was higher among those classified as MU/NW [ORWC, 1.48; 95% confidence interval (CI), 1.05–2.10 and ORWHR, 1.68; 95% CI, 1.21–2.35] and MU/OW (ORBMI, 2.38; 95% CI, 1.73–3.27; ORWC, 2.69; 95% CI, 1.92–3.77 and ORWHR, 1.83; 95% CI, 1.32–2.54). MH/OW individuals were also at increased endometrial cancer risk compared with MH/NW individuals (ORWC, 1.94; 95% CI, 1.24–3.04). Conclusions: Women with metabolic dysfunction appear to have higher risk of endometrial cancer regardless of their body size. However, OW status raises endometrial cancer risk even among women with lower insulin levels, suggesting that obesity-related pathways are relevant for the development of this cancer beyond insulin. Impact: Classifying women by metabolic health may be of greater utility in identifying those at higher risk for endometrial cancer than anthropometry per se.

[1]  M. Schulze,et al.  Prospective analysis of circulating metabolites and endometrial cancer risk , 2021, Gynecologic oncology.

[2]  James D. Johnson,et al.  Hyperinsulinemia in Obesity, Inflammation, and Cancer , 2021, Diabetes & metabolism journal.

[3]  U. Turpeinen,et al.  Adipose tissue estrogen production and metabolism in premenopausal women , 2021, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  Nam Hoon Kim,et al.  Effect of Metabolic Health and Obesity Phenotype on the Risk of Pancreatic Cancer: A Nationwide Population-Based Cohort Study , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[6]  N. Allen,et al.  Body size, body composition and endometrial cancer risk among postmenopausal women in UK Biobank , 2020, International journal of cancer.

[7]  K. Han,et al.  Increased incidence of bladder cancer with metabolically unhealthy status: analysis from the National Health Checkup database in Korea , 2020, Scientific Reports.

[8]  F. Magkos,et al.  Physiological and Lifestyle Traits of Metabolic Dysfunction in the Absence of Obesity , 2020, Current Diabetes Reports.

[9]  G. Shulman,et al.  Mechanistic Links between Obesity, Insulin, and Cancer. , 2020, Trends in cancer.

[10]  R. Monteiro,et al.  Metabolically Healthy Obesity—Heterogeneity in Definitions and Unconventional Factors , 2020, Metabolites.

[11]  Seung Hoon Lee,et al.  Metabolic Health, Obesity, and the Risk of Developing Open-Angle Glaucoma: Metabolically Healthy Obese Patients versus Metabolically Unhealthy but Normal Weight Patients , 2019, Diabetes & metabolism journal.

[12]  S. Klein,et al.  Metabolically healthy obesity: facts and fantasies. , 2019, The Journal of clinical investigation.

[13]  S. Menini,et al.  Metabolically healthy versus metabolically unhealthy obesity. , 2019, Metabolism: clinical and experimental.

[14]  Jason Gertz,et al.  Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions , 2019, Hormones and Cancer.

[15]  D. Moon,et al.  Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study , 2019, Journal of Korean medical science.

[16]  Mimi Y. Kim,et al.  Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women , 2018, International journal of cancer.

[17]  U. Turpeinen,et al.  Estrogen Metabolism in Abdominal Subcutaneous and Visceral Adipose Tissue in Postmenopausal Women , 2017, The Journal of clinical endocrinology and metabolism.

[18]  C. Weinberg,et al.  The association between metabolic health, obesity phenotype and the risk of breast cancer , 2017, International journal of cancer.

[19]  P. Hartge,et al.  Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial , 2017, International journal of cancer.

[20]  A. Tomiyama,et al.  Autophagic dysfunction is improved by intermittent administration of osteocalcin in obese mice , 2016, International Journal of Obesity.

[21]  E. Riboli,et al.  A Nested Case–Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2016, PLoS medicine.

[22]  Victoria S. Sprung,et al.  Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity , 2016, International Journal of Obesity.

[23]  Adrian V. Hernández,et al.  Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. , 2015, European journal of cancer.

[24]  D. Greenwood,et al.  Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  N. Mode,et al.  Validity of self-reported body mass index among middle-aged participants in the Norwegian Women and Cancer study , 2015, Clinical epidemiology.

[26]  J. Perry,et al.  Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis , 2015, Journal of the National Cancer Institute.

[27]  T. Rohan,et al.  Breast cancer risk in metabolically healthy but overweight postmenopausal women. , 2015, Cancer research.

[28]  Nicolas Wentzensen,et al.  Metabolic Syndrome and Risk of Endometrial Cancer in the United States: A Study in the SEER–Medicare Linked Database , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[29]  T. Rebbeck,et al.  Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2) , 2014, Cancer Causes & Control.

[30]  M. Singer,et al.  Metabolic Health Reduces Risk of Obesity-Related Cancer in Framingham Study Adults , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[31]  J. Chang-Claude,et al.  Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort--a factor analysis. , 2013, American journal of epidemiology.

[32]  L. Ries,et al.  Trends in Endometrial Cancer Incidence by Race and Histology with a Correction for the Prevalence of Hysterectomy, SEER 1992 to 2008 , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[33]  Yingmei Wang,et al.  Insulin resistance: a significant risk factor of endometrial cancer. , 2012, Gynecologic oncology.

[34]  Mimi Y. Kim,et al.  Incident Cardiovascular Disease Events in Metabolically Benign Obese Individuals , 2012, Obesity.

[35]  J. Reynolds,et al.  Visceral adiposity, insulin resistance and cancer risk , 2011, Diabetology & metabolic syndrome.

[36]  J. Manson,et al.  A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[37]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[38]  J. Chang-Claude,et al.  Serum levels of C‐peptide, IGFBP‐1 and IGFBP‐2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition , 2007, International journal of cancer.

[39]  J. Manson,et al.  Prospective Study of , 2007 .

[40]  C. Friedenreich,et al.  Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition , 2007, Cancer Causes & Control.

[41]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[42]  David B Allison,et al.  Metabolic and behavioral characteristics of metabolically obese but normal-weight women. , 2004, The Journal of clinical endocrinology and metabolism.

[43]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[44]  Jo Mitchell,et al.  Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study , 2003, Public Health Nutrition.

[45]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[46]  F. Clavel-Chapelon,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC) calibration study: rationale, design and population characteristics , 2002, Public Health Nutrition.

[47]  Harri Vainio,et al.  Overweight, obesity, and cancer risk. , 2002, The Lancet. Oncology.

[48]  T. Key,et al.  Validity of self-reported height and weight in 4808 EPIC–Oxford participants , 2002, Public Health Nutrition.

[49]  C. Stuart,et al.  Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. , 1998, American journal of obstetrics and gynecology.

[50]  C. Roberts,et al.  Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. , 1996, Endocrinology.

[51]  P. Garcia‐Webb,et al.  C-peptide measurement: methods and clinical utility. , 1984, Critical reviews in clinical laboratory sciences.

[52]  P. Siiteri,et al.  Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. , 1974, The Journal of clinical endocrinology and metabolism.